Dexcom has officially announced the clearance of its groundbreaking over-the-counter continuous glucose monitor, Stelo, by the U.S. Food and Drug Administration. Set to revolutionize diabetes care, Stelo will hit the online market this summer, offering a hassle-free monitoring solution for the more than 25 million Americans living with Type 2 diabetes who do not use insulin. This innovation marks the first time a glucose biosensor, which tracks glucose levels in real time and communicates data wirelessly to a smartphone, is available without a prescription, making advanced diabetes management accessible to a wider audience, including those without insurance coverage for such devices.
Designed specifically for non-insulin Type 2 diabetes patients, Stelo promises a simplified user experience without the complexity of numerous alerts and notifications typical in other devices aimed at more severe diabetes emergencies. According to Dexcom's COO, Jake Leach, the introduction of Stelo at an "approachable" cash price represents a significant step towards enhancing patient autonomy in diabetes management by providing insights into one's health without the need for medical intermediation. This strategic move not only expands access to crucial health monitoring technologies but also paves the way for broader insurance coverage as the benefits of Stelo become increasingly evident.
%20(1).jpg)
.png)
.png)
.png)